Barclays raised the firm’s price target on Fortrea (FTRE) to $8 from $6 and keeps an Underweight rating on the shares as part of a Q3 preview for the life science tools and diagnostics group. The firm views the companies’ end markets as stable with improvements likely going forward. In addition, investment sentiment “feels bottomed” as share valuations have come down, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FTRE:
- Fortrea Holdings Appoints William J. Sharbaugh as Director
- Fortrea price target raised to $9.50 from $7 at Jefferies
- Fortrea price target raised to $14 from $9 at Baird
- Fortrea Expands Inducement Award Plan for New Hires
- Cautious Hold Rating for Fortrea Holdings Inc. Amid Revenue Growth and Modest Margins